查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566754

人用胰島素市場：按產品類型、按適應症、按胰島素類型、按分銷管道：2024-2033 年全球機會分析和產業預測

Human Insulin Market By Product Type, By Indication By Type of Insulin By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 245 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

人類胰島素市場

2023年，人胰島素市值為171億美元，預計2024年至2033年複合年成長率為3.4%，到2033年達到240億美元。

人類胰島素是天然胜肽激素的合成模擬物，是在實驗室的大腸桿菌中合成的。有一種短效常規形式和一種稱為神經魚精蛋白哈格多恩胰島素的中間形式。人類胰島素取代人體自然產生的胰島素並調節血液中的血糖濃度。

人類胰島素市場的關鍵促進因素是全球糖尿病盛行率的不斷上升。與動物胰島素相比，人類胰島素因其功效高且過敏反應風險極低而受到患者和醫生的快速需求。人類胰島素市場的最新趨勢是，由於療效可比且成本效益更高，患者傾向於使用生物相似藥產品。

然而，其他替代品的存在，例如含有 GLP-1 受體促效劑的口服藥物和非胰島素注射藥物，對人類胰島素產生了顯著的競爭。此外，由於臨床前階段、臨床試驗和上市後安全監測等各階段的監管核准程序冗長，將人類胰島素推向市場是一個複雜且耗時的過程。這延遲了蛋白質的供應並限制了市場的開拓。相反，人工智慧和機器學習等資料主導方法的整合有望透過最佳化生產參數和預測產品產量來提高生產效率。

按部門審查

人類胰島素市場分為產品類型、適應症、胰島素類型、通路和地區。依產品類型分類，市場分為筆、注射器等。依適應症分為第1型糖尿病、第2型糖尿病和妊娠糖尿病。胰島素依類型分為速效胰島素、短效胰島素、中效胰島素等。依分銷管道分為醫院藥房、藥局和零售藥房以及線上供應商。從區域來看，分析包括北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

按產品類型分類，鋼筆細分市場將在 2023 年佔據主導地位。

有跡象表明，1 型糖尿病細分市場將在 2023 年取得較高的市場地位。

按胰島素類型分類，速效胰島素細分市場在 2023 年獲得了較高的市場佔有率。

按分銷通路分類，藥局/零售藥局細分市場在 2023 年佔據最高佔有率。

按地區分類，北美地區 2023 年收益最高。

該報告可以客製化。

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • 主要參與企業的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章依產品類型分類的人類胰島素市場

  • 市場概況
  • 筆
  • 注射器
  • 其他

第5章人類胰島素市場：依適應症分類

  • 市場概況
  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病

第6章 人用胰島素市場：按胰島素類型

  • 市場概況
  • 速效胰島素
  • 短效胰島素
  • 中效胰島素
  • 其他

第7章人胰島素市場：依通路分類

  • 市場概況
  • 醫院藥房
  • 藥局和零售藥局
  • 線上提供者

第8章人類胰島素市場：按地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國胰島素市場
    • 加拿大人胰島素市場
    • 墨西哥人胰島素市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 德國人胰島素市場
    • 法國人胰島素市場
    • 英國胰島素市場
    • 義大利人胰島素市場
    • 西班牙人胰島素市場
    • 其他歐洲人胰島素市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 日本人胰島素市場
    • 中國人胰島素市場
    • 印度人胰島素市場
    • 澳洲人胰島素市場
    • 韓國人胰島素市場
    • 其他亞太地區人類胰島素市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西人胰島素市場
    • 沙烏地人胰島素市場
    • 南非人胰島素市場
    • 其他拉丁美洲/中東/非洲人胰島素市場

第9章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第10章 公司簡介

  • Eli Lilly And Company
  • Sanofi
  • Novo Nordisk A/S
  • Pfizer
  • Biocon
  • Wockhardt
  • MannKind Corporation
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Medtronic
  • Lupin
簡介目錄
Product Code: A00321

Human Insulin Market

The human insulin market was valued at $17.1 billion in 2023 and is projected to reach $24.0 billion by 2033, growing at a CAGR of 3.4% from 2024 to 2033.

Human insulin is a synthetic mimic of the natural peptide hormone, which is synthesized in laboratory settings inside E. coli bacteria. It exists in two forms: a short-acting regular form and an intermediate-acting form known as neural protamine Hagedorn insulin. Human insulin replaces the naturally produced insulin inside the body and regulates the glucose levels in the blood.

A key driver of the human insulin market is increase in the prevalence of diabetes globally. In addition, human insulin is experiencing a surge in demand from patients and medical practitioners as compared to animal insulin owing to its high efficacy and minimal risk of allergic reactions. The latest trend in the human insulin market is the inclination of patients toward biosimilar products owing to their comparable efficacy and high cost-effectiveness.

However, the presence of other alternatives such as oral medications and non-insulin injectables, including GLP-1 receptor agonists, offers a significant competition to human insulin. Moreover, the introduction of human insulin into the market is a complex & time-consuming process due to the lengthy regulatory approval procedure at different stages, which include pre-clinical stages, clinical trials, and post-market safety monitoring. This delays the availability of the protein, thereby limiting the development of the market. On the contrary, the integration of data-driven approaches such as AI and machine learning is expected to speed up production efficiency by optimizing the production parameters and predicting product yields.

Segment Review

The human insulin market is segmented into product type, indication, type of insulin, distribution channel, and region. On the basis of product type, the market is divided into pens, syringes, and others. As per indication, it is classified into type 1 diabetes, type 2 diabetes, and gestational diabetes. Depending on type of insulin, it is categorized into rapid-acting insulin, short-acting insulin, intermediate-acting insulin, and others. According to distribution channel, it is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of product type, the pens segment dominated the market in 2023.

As per indication, the type-1 diabetes segment acquired high stakes in the market in 2023.

Depending on type of insulin, the rapid-acting insulin segment garnered a high market share in 2023.

According to distribution channel, the drug stores & retail pharmacies segment was the highest shareholder in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The major players operating in the global human insulin market include Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Pfizer, Biocon, Wockhardt, MannKind Corporation, Tonghua Dongbao Pharmaceutical Co., Ltd., Medtronic, and Lupin. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

  • Pens
  • Syringes
  • Others

By Indication

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes

By Type Of Insulin

  • Rapid-acting insulin
  • Short-acting insulin
  • Intermediate-acting insulin
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Eli Lilly and Company
    • Sanofi
    • Novo Nordisk A/S
    • Pfizer
    • Biocon
    • Wockhardt
    • MannKind Corporation
    • Tonghua Dongbao Pharmaceutical Co., Ltd.
    • Medtronic
    • Lupin

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: HUMAN INSULIN MARKET, BY PRODUCT TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Product Type
  • 4.2. Pens
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Syringes
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Others
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: HUMAN INSULIN MARKET, BY INDICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Indication
  • 5.2. Type 1 Diabetes
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Type 2 Diabetes
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Gestational Diabetes
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: HUMAN INSULIN MARKET, BY TYPE OF INSULIN

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Type of Insulin
  • 6.2. Rapid-acting Insulin
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Short-acting Insulin
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Intermediate-acting Insulin
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Others
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country

CHAPTER 7: HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Distribution Channel
  • 7.2. Hospital Pharmacies
    • 7.2.1. Key Market Trends, Growth Factors and Opportunities
    • 7.2.2. Market Size and Forecast, By Region
    • 7.2.3. Market Share Analysis, By Country
  • 7.3. Drug Stores And Retail Pharmacies
    • 7.3.1. Key Market Trends, Growth Factors and Opportunities
    • 7.3.2. Market Size and Forecast, By Region
    • 7.3.3. Market Share Analysis, By Country
  • 7.4. Online Providers
    • 7.4.1. Key Market Trends, Growth Factors and Opportunities
    • 7.4.2. Market Size and Forecast, By Region
    • 7.4.3. Market Share Analysis, By Country

CHAPTER 8: HUMAN INSULIN MARKET, BY REGION

  • 8.1. Market Overview
    • 8.1.1 Market Size and Forecast, By Region
  • 8.2. North America
    • 8.2.1. Key Market Trends and Opportunities
    • 8.2.2. Market Size and Forecast, By Product Type
    • 8.2.3. Market Size and Forecast, By Indication
    • 8.2.4. Market Size and Forecast, By Type of Insulin
    • 8.2.5. Market Size and Forecast, By Distribution Channel
    • 8.2.6. Market Size and Forecast, By Country
    • 8.2.7. U.S. Human Insulin Market
      • 8.2.7.1. Market Size and Forecast, By Product Type
      • 8.2.7.2. Market Size and Forecast, By Indication
      • 8.2.7.3. Market Size and Forecast, By Type of Insulin
      • 8.2.7.4. Market Size and Forecast, By Distribution Channel
    • 8.2.8. Canada Human Insulin Market
      • 8.2.8.1. Market Size and Forecast, By Product Type
      • 8.2.8.2. Market Size and Forecast, By Indication
      • 8.2.8.3. Market Size and Forecast, By Type of Insulin
      • 8.2.8.4. Market Size and Forecast, By Distribution Channel
    • 8.2.9. Mexico Human Insulin Market
      • 8.2.9.1. Market Size and Forecast, By Product Type
      • 8.2.9.2. Market Size and Forecast, By Indication
      • 8.2.9.3. Market Size and Forecast, By Type of Insulin
      • 8.2.9.4. Market Size and Forecast, By Distribution Channel
  • 8.3. Europe
    • 8.3.1. Key Market Trends and Opportunities
    • 8.3.2. Market Size and Forecast, By Product Type
    • 8.3.3. Market Size and Forecast, By Indication
    • 8.3.4. Market Size and Forecast, By Type of Insulin
    • 8.3.5. Market Size and Forecast, By Distribution Channel
    • 8.3.6. Market Size and Forecast, By Country
    • 8.3.7. Germany Human Insulin Market
      • 8.3.7.1. Market Size and Forecast, By Product Type
      • 8.3.7.2. Market Size and Forecast, By Indication
      • 8.3.7.3. Market Size and Forecast, By Type of Insulin
      • 8.3.7.4. Market Size and Forecast, By Distribution Channel
    • 8.3.8. France Human Insulin Market
      • 8.3.8.1. Market Size and Forecast, By Product Type
      • 8.3.8.2. Market Size and Forecast, By Indication
      • 8.3.8.3. Market Size and Forecast, By Type of Insulin
      • 8.3.8.4. Market Size and Forecast, By Distribution Channel
    • 8.3.9. UK Human Insulin Market
      • 8.3.9.1. Market Size and Forecast, By Product Type
      • 8.3.9.2. Market Size and Forecast, By Indication
      • 8.3.9.3. Market Size and Forecast, By Type of Insulin
      • 8.3.9.4. Market Size and Forecast, By Distribution Channel
    • 8.3.10. Italy Human Insulin Market
      • 8.3.10.1. Market Size and Forecast, By Product Type
      • 8.3.10.2. Market Size and Forecast, By Indication
      • 8.3.10.3. Market Size and Forecast, By Type of Insulin
      • 8.3.10.4. Market Size and Forecast, By Distribution Channel
    • 8.3.11. Spain Human Insulin Market
      • 8.3.11.1. Market Size and Forecast, By Product Type
      • 8.3.11.2. Market Size and Forecast, By Indication
      • 8.3.11.3. Market Size and Forecast, By Type of Insulin
      • 8.3.11.4. Market Size and Forecast, By Distribution Channel
    • 8.3.12. Rest of Europe Human Insulin Market
      • 8.3.12.1. Market Size and Forecast, By Product Type
      • 8.3.12.2. Market Size and Forecast, By Indication
      • 8.3.12.3. Market Size and Forecast, By Type of Insulin
      • 8.3.12.4. Market Size and Forecast, By Distribution Channel
  • 8.4. Asia-Pacific
    • 8.4.1. Key Market Trends and Opportunities
    • 8.4.2. Market Size and Forecast, By Product Type
    • 8.4.3. Market Size and Forecast, By Indication
    • 8.4.4. Market Size and Forecast, By Type of Insulin
    • 8.4.5. Market Size and Forecast, By Distribution Channel
    • 8.4.6. Market Size and Forecast, By Country
    • 8.4.7. Japan Human Insulin Market
      • 8.4.7.1. Market Size and Forecast, By Product Type
      • 8.4.7.2. Market Size and Forecast, By Indication
      • 8.4.7.3. Market Size and Forecast, By Type of Insulin
      • 8.4.7.4. Market Size and Forecast, By Distribution Channel
    • 8.4.8. China Human Insulin Market
      • 8.4.8.1. Market Size and Forecast, By Product Type
      • 8.4.8.2. Market Size and Forecast, By Indication
      • 8.4.8.3. Market Size and Forecast, By Type of Insulin
      • 8.4.8.4. Market Size and Forecast, By Distribution Channel
    • 8.4.9. India Human Insulin Market
      • 8.4.9.1. Market Size and Forecast, By Product Type
      • 8.4.9.2. Market Size and Forecast, By Indication
      • 8.4.9.3. Market Size and Forecast, By Type of Insulin
      • 8.4.9.4. Market Size and Forecast, By Distribution Channel
    • 8.4.10. Australia Human Insulin Market
      • 8.4.10.1. Market Size and Forecast, By Product Type
      • 8.4.10.2. Market Size and Forecast, By Indication
      • 8.4.10.3. Market Size and Forecast, By Type of Insulin
      • 8.4.10.4. Market Size and Forecast, By Distribution Channel
    • 8.4.11. South Korea Human Insulin Market
      • 8.4.11.1. Market Size and Forecast, By Product Type
      • 8.4.11.2. Market Size and Forecast, By Indication
      • 8.4.11.3. Market Size and Forecast, By Type of Insulin
      • 8.4.11.4. Market Size and Forecast, By Distribution Channel
    • 8.4.12. Rest of Asia-Pacific Human Insulin Market
      • 8.4.12.1. Market Size and Forecast, By Product Type
      • 8.4.12.2. Market Size and Forecast, By Indication
      • 8.4.12.3. Market Size and Forecast, By Type of Insulin
      • 8.4.12.4. Market Size and Forecast, By Distribution Channel
  • 8.5. LAMEA
    • 8.5.1. Key Market Trends and Opportunities
    • 8.5.2. Market Size and Forecast, By Product Type
    • 8.5.3. Market Size and Forecast, By Indication
    • 8.5.4. Market Size and Forecast, By Type of Insulin
    • 8.5.5. Market Size and Forecast, By Distribution Channel
    • 8.5.6. Market Size and Forecast, By Country
    • 8.5.7. Brazil Human Insulin Market
      • 8.5.7.1. Market Size and Forecast, By Product Type
      • 8.5.7.2. Market Size and Forecast, By Indication
      • 8.5.7.3. Market Size and Forecast, By Type of Insulin
      • 8.5.7.4. Market Size and Forecast, By Distribution Channel
    • 8.5.8. Saudi Arabia Human Insulin Market
      • 8.5.8.1. Market Size and Forecast, By Product Type
      • 8.5.8.2. Market Size and Forecast, By Indication
      • 8.5.8.3. Market Size and Forecast, By Type of Insulin
      • 8.5.8.4. Market Size and Forecast, By Distribution Channel
    • 8.5.9. South Africa Human Insulin Market
      • 8.5.9.1. Market Size and Forecast, By Product Type
      • 8.5.9.2. Market Size and Forecast, By Indication
      • 8.5.9.3. Market Size and Forecast, By Type of Insulin
      • 8.5.9.4. Market Size and Forecast, By Distribution Channel
    • 8.5.10. Rest of LAMEA Human Insulin Market
      • 8.5.10.1. Market Size and Forecast, By Product Type
      • 8.5.10.2. Market Size and Forecast, By Indication
      • 8.5.10.3. Market Size and Forecast, By Type of Insulin
      • 8.5.10.4. Market Size and Forecast, By Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top Winning Strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

  • 10.1. Eli Lilly And Company
    • 10.1.1. Company Overview
    • 10.1.2. Key Executives
    • 10.1.3. Company Snapshot
    • 10.1.4. Operating Business Segments
    • 10.1.5. Product Portfolio
    • 10.1.6. Business Performance
    • 10.1.7. Key Strategic Moves and Developments
  • 10.2. Sanofi
    • 10.2.1. Company Overview
    • 10.2.2. Key Executives
    • 10.2.3. Company Snapshot
    • 10.2.4. Operating Business Segments
    • 10.2.5. Product Portfolio
    • 10.2.6. Business Performance
    • 10.2.7. Key Strategic Moves and Developments
  • 10.3. Novo Nordisk A/S
    • 10.3.1. Company Overview
    • 10.3.2. Key Executives
    • 10.3.3. Company Snapshot
    • 10.3.4. Operating Business Segments
    • 10.3.5. Product Portfolio
    • 10.3.6. Business Performance
    • 10.3.7. Key Strategic Moves and Developments
  • 10.4. Pfizer
    • 10.4.1. Company Overview
    • 10.4.2. Key Executives
    • 10.4.3. Company Snapshot
    • 10.4.4. Operating Business Segments
    • 10.4.5. Product Portfolio
    • 10.4.6. Business Performance
    • 10.4.7. Key Strategic Moves and Developments
  • 10.5. Biocon
    • 10.5.1. Company Overview
    • 10.5.2. Key Executives
    • 10.5.3. Company Snapshot
    • 10.5.4. Operating Business Segments
    • 10.5.5. Product Portfolio
    • 10.5.6. Business Performance
    • 10.5.7. Key Strategic Moves and Developments
  • 10.6. Wockhardt
    • 10.6.1. Company Overview
    • 10.6.2. Key Executives
    • 10.6.3. Company Snapshot
    • 10.6.4. Operating Business Segments
    • 10.6.5. Product Portfolio
    • 10.6.6. Business Performance
    • 10.6.7. Key Strategic Moves and Developments
  • 10.7. MannKind Corporation
    • 10.7.1. Company Overview
    • 10.7.2. Key Executives
    • 10.7.3. Company Snapshot
    • 10.7.4. Operating Business Segments
    • 10.7.5. Product Portfolio
    • 10.7.6. Business Performance
    • 10.7.7. Key Strategic Moves and Developments
  • 10.8. Tonghua Dongbao Pharmaceutical Co., Ltd.
    • 10.8.1. Company Overview
    • 10.8.2. Key Executives
    • 10.8.3. Company Snapshot
    • 10.8.4. Operating Business Segments
    • 10.8.5. Product Portfolio
    • 10.8.6. Business Performance
    • 10.8.7. Key Strategic Moves and Developments
  • 10.9. Medtronic
    • 10.9.1. Company Overview
    • 10.9.2. Key Executives
    • 10.9.3. Company Snapshot
    • 10.9.4. Operating Business Segments
    • 10.9.5. Product Portfolio
    • 10.9.6. Business Performance
    • 10.9.7. Key Strategic Moves and Developments
  • 10.10. Lupin
    • 10.10.1. Company Overview
    • 10.10.2. Key Executives
    • 10.10.3. Company Snapshot
    • 10.10.4. Operating Business Segments
    • 10.10.5. Product Portfolio
    • 10.10.6. Business Performance
    • 10.10.7. Key Strategic Moves and Developments